| Diabetes Mellitus

Afrezza - (Insulin Human) Inhalation Powder vs Fiasp

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.

Deep comparison between: Afrezza vs Fiasp with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsFiasp has a higher rate of injection site reactions vs Afrezza based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Fiasp but not Afrezza, including UnitedHealthcare

Category

Afrezza

Fiasp

At A Glance

RouteOral inhalation

FrequencyAt each meal

ClassRapid-acting insulin

RouteSC injection

FrequencyWith meals

ClassRapid-acting insulin analog

Indications

Diabetes Mellitus

Diabetes Mellitus

Dosing

Diabetes Mellitus Insulin-naive patients: 4 units inhaled at the beginning of each meal; patients switching from subcutaneous mealtime insulin convert per table (up to 3 units -> 4 units, 4-5 units -> 8 units, 6-7 units -> 12 units, >=8 units -> 16 units); adjust dose based on metabolic needs, blood glucose monitoring, and glycemic control goal.

Diabetes Mellitus - SC injection Inject at start of meal or within 20 minutes after starting a meal into abdomen, upper arm, or thigh; generally use with intermediate- or long-acting insulin; individualize dose based on metabolic needs and blood glucose monitoring.

Diabetes Mellitus - Insulin pump (CSII) Administer by continuous SC infusion using an insulin pump; change FIASP reservoir at least every 6 days or PumpCart at least every 4 days; do not mix with other insulins in the pump.

Diabetes Mellitus - IV infusion Administer only under medical supervision; dilute to 0.5-1 unit/mL in polypropylene infusion bags with 0.9% sodium chloride or 5% dextrose; stable at room temperature for 24 hours.

Contraindications

Episodes of hypoglycemia
Chronic lung disease such as asthma or COPD due to risk of acute bronchospasm
Previous severe hypersensitivity reaction to any regular human insulin product or any inactive ingredient in AFREZZA

Episodes of hypoglycemia
Known hypersensitivity to insulin aspart or any excipient in FIASP

Drug Interactions

375View drug interactions

374View drug interactions

Adverse Reactions

Most common (>=2%) Cough, throat pain or irritation, headache, diarrhea, productive cough, fatigue, nausea

Serious Acute bronchospasm, hypoglycemia, decline in pulmonary function, lung cancer, diabetic ketoacidosis, hypersensitivity reactions

Postmarketing Bronchospasm

Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, nausea, diarrhea, back pain (adults with T1D); urinary tract infection (adults with T2D); viral upper respiratory tract infection, upper respiratory tract infection, influenza, headache, pyrexia, vomiting (pediatric T1D)

Serious Hypoglycemia, hypokalemia, severe hypersensitivity reactions including anaphylaxis, angioedema, bronchospasm, hypotension, and shock; lipodystrophy; injection or infusion site reactions; peripheral edema; weight gain

Postmarketing Localized cutaneous amyloidosis at injection site; hyperglycemia with repeated injections into amyloidosis areas; hypoglycemia with sudden change to unaffected injection site

Pharmacology

Insulin lowers blood glucose in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production; it also inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.

Rapid-acting insulin analog; binds to insulin receptors to lower blood glucose by facilitating cellular uptake of glucose into skeletal muscle and adipose tissue and inhibiting hepatic glucose output, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Afrezza